Skip to content
DataLookout
Menu

NCT07058883

Evaluation of Juläine (TM) for the Treatment of Atrophic Facial Acne Scars

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 12 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2026 to Jan 2028 Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Mar 2027 to Apr 30, 2028
    • Start date pushed from Mar 13, 2026 to Mar 16, 2026
    • Site details revised at 2 of 2 sites
  2. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: 4 to 3
    • Study description shortened, about 7 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2026 to Mar 13, 2026
    • Site details revised at 2 of 2 sites
    v6
  4. Notable Start date: Feb 2026 to Apr 2026v5
  5. Notable Start date: Nov 2025 to Feb 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Aug 2025 to Nov 2025v3
  2. Minor Secondary endpoints: details revised at 4 of 4 entries
    • Study title shortened, about 4 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Average change in Acne Scars from baseline to 6 and 12 months after treatment
Timeframe: 12 months after treatment

Secondary (3)

Change in skin elasticity and hydration measured by cutometry
Global improvement based on GAIS evaluated by investigator and patient
Change in scar structure using high-frequency ultrasound (HFUS)

Arms and interventions

Juläine GroupExperimental

Participants in this arm will receive three intradermal injections of Juläine, an injectable polylactic acid gel, at Day 0, Day 30, and Day 60. Injections are administered into areas affected by atrophic acne scars.

Placebo GroupPlacebo comparator

Participants in this arm will receive three intradermal injections of sterile saline (placebo) at Day 0, Day 30, and Day 60, into areas affected by acne scars.

Devices: Juläine

Other: Sterile Saline (Placebo)

Sites

2 sites in 1 country